主要成就
主要成就（截至2016-03-31）
（1）阐明人表皮生长因子受体（EGFR）激酶区多种突变导致非小细胞肺癌发生或耐药的分子机理（参见已发表研究论文5、6）；
（2）并在此基础上作为主要贡献者之一研发成功第一个高选择性、低毒性的治疗EGFR T790M耐药性肺癌的抑制剂WZ-4002（第三代药）（参见已发表研究论文7）；
（3）作为主要贡献者之一研发成功第一个抗T790M/C797S（该突变对WZ-4002、CO-1686和AZD9291耐药）的新一代抗耐药性肺癌异位型抑制剂EAI045（第四代药）（参见已接收待刊发研究论文21）。
研究论文（截至2016-03-31）
“(#)”表示第一作者或并列第一作者，“(*)”表示通讯作者或并列通讯作者。
已获得杂志正式接收函，等待印刷刊发的论文：
22) Anastasi S(#), Zhu SJ(#), Ballarò C, Manca S, Lamberti D, Wang LJ, Alemà S, Yun CH(*), Segatto O(*), Lack of evidence that CYTH2/ARNO functions as a direct intracellular EGFR activator, Cell, accepted.
21) Jia Y(#), Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, J？nne PA, Eck MJ(*), Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors, Nature, accepted.
已刊发研究论文（已可通过PubMed检索）：
20) Begley MJ(#), Yun CH, Gewinner CA, Asara JM, Johnson JL, Coyle AJ, Eck MJ, Apostolou I, Cantley LC(*). EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. Nat Struct Mol Biol, 2015 Dec;22(12):983-90.
19) Liu L(#), Chen JY(#), Yang B, Wang FH, Wang YH(*), Yun CH(*), Active state structures of a small heat shock protein revealed a molecular switch for chaperone function, Structure, 2015 Nov 3;23(11):2066-75.
18) Wu H(#), Wang A(#), Zhang W(#), Wang B(#), Chen C(#), Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, Wang J, Wang C, Weisberg EL, Gray NS, Yun CH, Liu J(*), Chen L(*), Liu Q(*). Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget. 2015 Oct 13;6(31):31313-22.
17) Liang Y(#), Fu Y, Qi R, Wang M, Yang N, He L, Yu F, Zhang J, Yun CH, Wang X, Liu J, Kong W(*), Cartilage oligomeric matrix protein is a natural inhibitor of thrombin, Blood, 2015 Aug 13;126(7):905-14.
16) Ercan D(#), Choi HG(#), Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS(*), Janne PA(*), EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors, Clin Cancer Res, 2015 Sep 1;21(17):3913-23.
15) Tan L(#), Wang J(#), Tanizaki J(#), Huang Z(#), Aref AR(#), Rusan M, Zhu SJ, Zhang Y, Ercan D, LiaoRG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS(*), Mohammadi M(*), J？nne PA(*), Gray NS(*), Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors, Proc Natl Acad Sci U S A, 2014 Nov11;111(45):E4869-77.
14) Yasuda H(#), Park E(#), Yun CH(#), Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ(*),Kobayashi SS(*), Costa DB(*), Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20insertion mutations in lung cancer, Sci Transl Med, 2013 Dec18;5(216):216ra177.
13) Red Brewera M(#), Yun CH, Laia D, Lemmon MA, Eck MJ, Pao W(*),Mechanism for activation of mutated epidermal growth factor receptors in lung cancer, Proc Natl Acad Sci USA, 2013 Sep 17; 110(38):E3595-604.
12) Zhang C(#), Lopez MS, Dar AC, Ladow E, Finkbeiner S, Yun CH, Eck MJ, Shokat KM(*),Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology, ACS Chem Biol, 2013 Sep 20; 8(9):1931-8.
11) Tu D(#), Zhu Z(#), Zhou AY, Yun CH, Lee KE, Toms AV, Li Y, Dunn GP, Chan E, Thai T, Yang S, Ficarro SB, Marto JA, Jeon H, Hahn WC, Barbie DA(*), Eck MJ(*), Crystal Structure of Tank-binding Kinase 1, Cell Rep, 2013 Mar 28; 3(3):747-58.
10) Greulich H(#)(*), Kaplan B, Mertins P, Chen TH, Tanaka K, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck M, Mani DR, Jaffe JD, Carr SA, Wong KK, and Meyerson M, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2, ProcNatl Acad Sci USA,2012 Sep 4; 109(36):14476-81.
9) He M(#), Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Janne PA, Ladanyi M(*), Oxnard GR, EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma, Clin Cancer Res, 2012 Mar 15; 18(6):1790-7.
8) Eck MJ(#)(*), Yun CH, Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta, 2010 Mar; 1804(3): 559-66. (Invited review)
7) Zhou W(#), Ercan D(#), Chen L(#), Yun CH(#), Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS(*), J？nne PA(*), Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 2009 Dec 24; 462(7276):1070-4.
6) Yun CH(#), Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, and Eck MJ(*), The T790Mgatekeeper mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc Natl Acad Sci USA, 2008Feb 12; 105(6):2070-5.
5) Yun CH(#), Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, and Eck MJ(*), Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity, Cancer Cell, 2007 Mar; 11(3):217-27. (Cover story)
4) Blair JA(#), Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA and Shokat KM(*), Structure-guided development of affinity probes for tyrosine kinases using chemical genetics, Nat Chem Biol, 2007 Apr; 3(4):229-38.
3) Wang T(#), Yun CH, Gu SY, Chang WR and Liang DC(*), 1.88 ？ crystal structure of the C domain of hCyP33: A novel domain of peptidyl-prolyl cis-transisomerase, Biochem Biophys Res Commun, 2005 Aug 5; 333(3):845-9.
2) Yun CH(#), Tang YH, Feng YM, An XM, Chang WR and Liang DC(*), 1.42 ？ crystal structure of mini-IGF-1(2): an analysis of the disulfide isomerization property and receptor binding property of IGF-1 based on the three-dimensional structure, Biochem Biophys Res Commun, 2005 Jan 7; 326(1):52-9.
1) Yun CH(#), Bai J, Sun DY, Cui DF, Chang WR and Liang DC(*), Structure of potato calmodulin PCM6: the first report of the three-dimensional structure of a plant calmodulin, Acta Crystallogr D Biol Crystallogr, 2004 Jul; 60(Pt 7):1214-9.
